Compare First Solar, Inc. (FSLR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? First Solar, Inc. trades at $176.5 (market cap $20.05B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: First Solar, Inc. is far larger — about 4.1× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FSLR | TVTX | |
|---|---|---|
Market Cap | $20.05B | $4.88B |
Volume | 2,420,017 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $318.30 | $67.52 |
52-Week Low | $172.11 | $26.79 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $18.52B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $186.60, up 3.83% today, but remains in a bearish technical trend with resistance near $190. The company reported strong revenue growth to $5.22 billion in 2025 and a net income margin of 32.47%, though it missed Q4 2025 EPS estimates. Recent news includes a patent lawsuit against competitors and elevated put option activity, reflecting mixed sentiment amid sector-wide pressures from high borrowing costs.
FSLR presents a value opportunity with a low P/E of 11.5 and analyst consensus price target of $269, but faces risks from solar industry headwinds and technical bearish signals. Earnings beats in recent quarters support fundamentals, yet political and financing challenges could limit near-term upside.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
